First patient dosed with LNK001 in Ph 1 study in patients with advanced or metastatic clear cell RCC October 6, 2026
Perioperative Imfinzi plus neoadjuvant enfortumab vedotin granted Priority Review in the US for MIBC patients October 1, 2026
FDA Approves WELIREG + LENVIMA for Certain Previously Treated Adult Patients With clear cell RCC October 1, 2026
Positive EU CHMP Opinion for KEYTRUDA + Padcev as Perioperative Treatment for Adults With Resectable MIBC September 22, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
FDA clears IND application for ADI-212 for the treatment of patients with metastatic CRPC September 2, 2026
First Patient Dosed in MODeFIRe-1 Ph 2 Study of MRT-2359 + Apalutamide in Patients with AR Mutation-Positive Metastatic CRPC August 25, 2026
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer July 28, 2026
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan-Tivozanib Combination for Advanced Kidney Cancer Patients July 28, 2026
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer July 28, 2026
Durable Clinical Activity of Darlifarnib + Cabozantinib Reported in Cabozantinib-Naïve Clear Cell RCC Patients July 28, 2026
FDA Grants Priority Review for TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer July 28, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With Padcev, as Treatment Before and After Surgery for Adults With MIBC July 15, 2026
IND application for HLX3902 approved in China for treatment of metastatic CRPC and solid tumors June 23, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each With WELIREG, for Adjuvant Treatment of Certain Patients With Clear Cell RCC June 17, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares June 17, 2026
